Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media. - Wikidata - awgldk - TriplyDB

Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.

Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.

http://www.wikidata.org/entity/Q34883537

about

Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.

http://www.wikidata.org/entity/Q34883537

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@ast

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@en

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@nl

type

label

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@ast

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@en

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@nl

prefLabel

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@ast

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@en

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@nl

P1433

Q34883537-4C035021-CC66-4AA7-968C-EBCC2D783E09

P1476

Q34883537-EA87C321-61CA-49CA-A348-FE59A6D7B0FD

P2093

Q34883537-243778C1-7017-4CFB-BAC0-2156263F989B

Q34883537-3571D8A2-180C-43D1-BE83-04E1419CE63F

Q34883537-4BA8575F-DCEE-4B5C-9B14-4C4755F89B74

Q34883537-6B951F2D-495F-4939-9CEE-0818A43B967D

Q34883537-B7F96290-D7A7-4347-8CB0-91334122CFC1

Q34883537-C1B8A694-42D1-434A-A568-9E4520625DBB

Q34883537-C8BC5829-4197-4804-8FE1-3F2506527A91

Q34883537-CAD63D54-CB6D-4A26-9480-4F069AD1B92F

Q34883537-D691A958-A303-4079-8E37-EADE0E836427

Q34883537-E1298711-78AD-4280-BD99-7CCBC0BF58DF

P2860

Q34883537-12A04CA5-FBEB-44D8-944B-627C884FF751

Q34883537-227E4FD6-4DF4-452F-A21D-47AC8CB7C6CF

Q34883537-2E409465-4097-4788-B8A1-F7C3C05230AD

Q34883537-305F34FC-5578-4B24-961B-8EBA353704EC

Q34883537-37B7ED22-AD7A-46AF-96CD-8817F41D1EE4

Q34883537-4776A955-406B-47E3-A16E-086F4667E4E0

Q34883537-48F49B21-4CD5-4488-8C11-1978BB5E45D9

Q34883537-5092D113-18D3-4E32-A3F1-76BEE052682A

Q34883537-56B2864B-B541-44AB-AFB3-D0B7C961C79E

Q34883537-5C19BA54-C369-466E-BDA9-2AB992D71A6C

P304

Q34883537-75C8C670-2A3C-409F-9E89-C27553C2F048

P31

Q34883537-56171B95-80F9-4D50-955F-AF7D276DAFB7

P356

Q34883537-A078A9D6-708B-4582-A545-7CC024236DA0

P407

Q34883537-6767248F-22BA-4A7E-9A68-0FB2288F392D

P433

Q34883537-379F2391-81F1-4957-8A66-3A8E7D9EFFF9

P478

Q34883537-6403CE08-DB14-448B-8074-06B7D4EDD5AC

P577

Q34883537-D36A6DE2-0B44-4A3B-9183-7DBF8E0728DA

P5875

Q34883537-98547AEC-9E24-49CE-8F8C-A885A6CEC7C2

P698

Q34883537-D445565D-7FA3-4EBD-A01C-026E31D885F6

P932

Q34883537-907A7841-2F4E-402E-B199-826781FEEC5A

P356

AAC.47.4.1355-1363.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and efficacy ...... ae-induced acute otitis media.

@en

P2093

Donald P Smith

http://www.w3.org/2001/XMLSchema#string

Gary E Zurenko

http://www.w3.org/2001/XMLSchema#string

Ivan M Richards

http://www.w3.org/2001/XMLSchema#string

Jana L Jensen

http://www.w3.org/2001/XMLSchema#string

John J Biermacher

http://www.w3.org/2001/XMLSchema#string

Mark H Shattuck

http://www.w3.org/2001/XMLSchema#string

Ming-Shang T Kuo

http://www.w3.org/2001/XMLSchema#string

Raymond J Zielinski

http://www.w3.org/2001/XMLSchema#string

Ronda D Schaadt

http://www.w3.org/2001/XMLSchema#string

William R Humphrey

http://www.w3.org/2001/XMLSchema#string

P2860

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

Management of otitis media: 2000 and beyond.

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms.

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections.

Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Intrapulmonary pharmacokinetics of linezolid

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

P304

1355-1363

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.4.1355-1363.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10839872

http://www.w3.org/2001/XMLSchema#string

P698

12654670

http://www.w3.org/2001/XMLSchema#string

P932

152499

http://www.w3.org/2001/XMLSchema#string